Similarly, an analysis of large RA registry (CORRONA) showed reduction of CV events risk in patients treated with anti-TNF-α compared with patients treated with MTX and other nonbiological DMARDs [45]. This evidence concerns the gene TNF and rheumatoid arthritis.